November 6, 2017 Pharmacosmos starts head-to-head study comparing the incidence of hypophosphatemia after administration with Monofer® (iron isomaltoside) vs ferric carboxymaltose

Pharmacosmos announces that the first patient has been enrolled in Phosphare; a set of three Phase III comparative clinical trials evaluating the incidence and extent of IV iron-induced hypophosphatemia between Monofer® (iron isomaltoside) and Injectafer® /Ferinject® (ferric carboxymaltose) in adults with iron deficiency.

These studies are the first ever prospective head to head studies between Monofer® (iron isomaltoside) and Injectafer® /Ferinject® (ferric carboxymaltose).

The first two Phosphare studies are being conducted in US patients suffering iron deficiency from mixed aetiologies, the last study is conducted in European patients suffering from IBD. Approximately 400 patients will be included in the studies.


VP Marketing and Medical Affairs
Claes Strom



About Monofer®

Monofer® (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration. Monofer® is already marketed in more than 30 countries, primarily in Europe, for the treatment of iron deficiency anaemia. Monofer® is under development in the rest of the world, including North America and Japan. Monofer® is manufactured by Pharmacosmos, Denmark.

About Iron Deficiency

Iron deficiency is a debilitating condition that affects almost 1 billion people worldwide[i]. Iron deficiency is often associated with many chronic diseases such as renal diseases (including Chronic Kidney Disease), cancers (including chemotherapy induced anaemia), gynaecologic disorders (including abnormal uterine bleeding) and gastrointestinal diseases (including inflammatory bowel disease).

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, Germany, UK and US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.